Citation Impact
Citing Papers
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Heparin-Protein Interactions
2002 Standout
Heart rate variability in patients with ventricular arrhythmias: Effect of antiarrhythmic drugs
1991
Cardiovascular and Metabolic Alterations in Mice Lacking Both β1- and β2-Adrenergic Receptors
1999 StandoutNobel
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
2008 Standout
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
1996
Pharmacokinetics of Cardiovascular Drugs in Children
1994
Subtype selective regulation of coupling of rat cardiac ß adrenoceptors to adenylate cyclase
1993
Hypertension in the Very Elderly Trial (HYVET)
2001
Corticosteroid effect on early beta-adrenergic down-regulation durign circulatory shock: Hemodynamic study and beta-adrenergic receptor assay
1995
Drug-Induced Hepatotoxicity
2003 Standout
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.
1988
Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: Safety and cost efficacy
1997
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Mechanisms of Actions of Inhaled Anesthetics
2003 Standout
Molecular and cellular mechanisms of general anaesthesia
1994 StandoutNature
Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006
2006
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
1991 Standout
Anesthesiology
1997 Standout
A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease
1999 Standout
The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone
1990
Parenteral inotropic support for advancedcongestive heart failure
1998
Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
2005
Massive verapamil ingestion: A report of two cases and a review of the literature
1989
Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia
1996 Standout
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
2008 Standout
Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study
1996
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
PHARMACOLOGY OF PEDIATRIC RESUSCITATION
1997
Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: A preliminary study
1998
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial
1999
Enzymatic functionalization of carbon–hydrogen bonds
2010 StandoutNobel
The noncompetitive N-methyl-d-aspartate receptor antagonist, MK-801 profoundly reduces volatile anesthetic requirements in rabbits
1989
Myocarditis
2000 Standout
The ChEMBL database in 2017
2016 Standout
Cyclosporine
1989 Standout
State-dependent Block of Human Cardiac hNav1.5 Sodium Channels by Propafenone
2005
Pharmacokinetic and Pharmacodynamic Comparisons of Twice Daily and Four Times Daily Formulations of Procainamide in Patients with Frequent Ventricular Premature Depolarization
1996
The Transforming Growth Factor‐Betas: A New Family of Immunoregulatory Molecules
1990
Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: Demonstration in human subjects and verification in a paced canine model of ventricular failure
1991
Interventions to Enhance Patient Adherence to Medication Prescriptions
2002 Standout
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
2005 Standout
Influence of Hypertonic Saline Solution Infusion on Defibrillation Efficacy
1996
Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter
1989
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
1995
Long-term outcome with the automatic implantable cardioverter-defibrillator
1989
Calcium Antagonists in the Elderly
1996
Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux.
1981
Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure
1986
Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice
1998 StandoutNobel
Atrial fibrillation following coronary artery bypass surgery
1989
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias
1997 Standout
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
Carnitine Palmitoyltransferase (CPT) Modulators: A Medicinal Chemistry Perspective on 35 Years of Research
2011
Atrial Fibrillation Begets Atrial Fibrillation
1995 Standout
Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
2001
Coupling of β2-Adrenoceptor to GiProteins and Its Physiological Relevance in Murine Cardiac Myocytes
1999 StandoutNobel
In Vitro Desensitization of Beta Adrenergic Receptors in Human Neutrophils. ATTENUATION BY CORTICOSTEROIDS
1983 StandoutNobel
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
1992
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
1984 Standout
Use of catecholamines in pediatrics
1984
Clinical Pharmacokinetics of Cyclosporin
1986
Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist Pirbuterol
1981
Determinants of Survival in Patients with Ventricular Tachyarrhythmias
1983
Sympatholytic Action of Intravenous Amiodarone in the Rat Heart
1995
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
1993
Mechanisms of Membrane-Receptor Regulation
1984 StandoutNobel
Pharmacology of the Na v 1.1 domain IV voltage sensor reveals coupling between inactivation gating processes
2017 StandoutNobel
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.
1993 Standout
Chemoenzymatic elaboration of monosaccharides using engineered cytochrome P450 BM3 demethylases
2009 StandoutNobel
Metal–Organic Frameworks in Biomedicine
2011 Standout
Heart Rate Variability
1996 Standout
Heart rate variability: Standards of measurement, physiological interpretation, and clinical use
1996 Standout
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
Role of cardiac biopsy in the diagnosis and management of cardiac disease
1984
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Part 14: Pediatric Advanced Life Support
2010 Standout
Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts
1982 Standout
Part 8: Adult Advanced Cardiovascular Life Support
2010 Standout
Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction
2000 StandoutNobel
Hypersensitivity to Adrenergic Stimulation after Propranolol Withdrawal in Normal Subjects
1977
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
1990
Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise
1987
Inotropes and Vasopressors
2008
RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE
2004
Structure and Chemistry of Cytochrome P450
2005 Standout
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
1988
Characterization of two cDNAs encoding folate-binding proteins from L1210 murine leukemia cells. Increased expression associated with a genomic rearrangement.
1991 StandoutNobel
Works of Robert E. Kates being referenced
Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine.
1988
Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog.
1982
Pharmacodynamics of Procainamide in Patients With Ventricular Tachyarrhythmias
1988
Myocardial disposition of amiodarone in the dog.
1983
Simple and rapid high-performance liquid chromatographic analysis of cyclosporine in human blood and serum
1984
Dobutamine pharmacokinetics in severe heart failure
1978
Calcium Antagonists Pharmacokinetic Properties
1983
Verapamil disposition kinetics in chronic atrial fibrillation
1981
Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
1983
Effects of encainide and its metabolites on energy requirements for defibrillation.
1986
High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil.
1980
Prolongation of verapamil elimination kinetics during chronic oral administration
1982
Safety and Rationale for Continuation of Propranolol Therapy During Coronary Bypass Operation
1978
Clinical pharmacology of propafenone.
1983
Clinical importance of metabolites of antiarrhythmic drugs
1984
High-performance liquid chromatographic analysis of propafenone in human plasma samples
1982
Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia
1983
Pharmacodynamics of Inotropic and Chronotropic Responses to Oral Therapy with Propranolol
1978
Increased methotrexate toxicity due to concurrent probenecid administration
1976
Metabolite cumulation during chronic propafenone dosing in arrhythmia
1985
Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.
1982
New Antiarrhythmic Drugs
1981
Tolerance to dobutamine after a 72 hour continuous infusion
1980
The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure
1979
Negative Inotropic Effect of Lidocaine in Patients with Coronary Arterial Disease and Normal Subjects
1977
Verapamil Decreases MAC for Halothane in Dogs
1983
Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris
1981
Verapamil protein binding in patients and in normal subjects
1981